EAU 2025 | Assessing the availability of theranostics in low & middle-income countries

Mike Sathekge • 17 Mar 2025

EAU 2025

Genitourinary Cancer

Mike Sathekge, MBChB, University of Pretoria, Pretoria, South Africa, comments on the accessibility of the latest theranostics, which are currently limited to the affluent, but emphasizes the need to make them affordable and accessible to all. The current approval and trial landscape disproportionately benefits high-income countries, excluding low and middle-income countries from participating in these technologies. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.